Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

FDA 510(k)

LymphaTech Mobile 3D Measuring Tool

K-Number: K251255 · 2025-07-22

ApplicantLymphatech, Inc.
Decision Date2025-07-22
Product CodeSFG
Advisory CommitteeSU
DecisionSubstantially Equivalent

Device Summary

LymphaTech Mobile 3D Measuring Tool is the device name listed in this FDA 510(k) record. The listed applicant is Lymphatech, Inc.. It received FDA 510(k) clearance on 2025-07-22 under 510(k) number K251255. The device is classified under product code SFG. It was reviewed by the SU advisory panel. FDA Decision: Substantially Equivalent.

Frequently Asked Questions

What is the LymphaTech Mobile 3D Measuring Tool?

LymphaTech Mobile 3D Measuring Tool is a medical device that received FDA 510(k) clearance on 2025-07-22. The listed applicant is Lymphatech, Inc.. The 510(k) number is K251255.

When did LymphaTech Mobile 3D Measuring Tool receive FDA 510(k) clearance?

LymphaTech Mobile 3D Measuring Tool received FDA 510(k) clearance on 2025-07-22, under 510(k) number K251255.

Who is the listed applicant for LymphaTech Mobile 3D Measuring Tool?

The FDA 510(k) record lists Lymphatech, Inc. as the applicant. This does not by itself establish the device manufacturer.

What is the FDA product code for LymphaTech Mobile 3D Measuring Tool?

The FDA product code for LymphaTech Mobile 3D Measuring Tool is SFG.

Related Clinical Trials

Related records are matched automatically using names, product codes, or other metadata. A match does not establish a verified clinical, scientific, corporate, or regulatory relationship; review the linked official sources.

NCT07608549FLASH Pilot Phase 1 Safety StudyNOT_YET_RECRUITINGNCT06562205PAP Systems External Clinical Studies (ECS)NOT_YET_RECRUITINGNCT04745156A Study Using Brain Stimulation and Behavioral Therapy to Increase Extent of Resection in Low-Grade GliomasNOT_YET_RECRUITINGNCT06443177The Effect of Sympathetic Modulation on Cerebral Vasospasm Secondary to Aneurysmal Subarachnoid HemorrhageSUSPENDED

Official Source

View on FDA Database →

Data sourced from FDA Open API. For the most current and authoritative information, always refer to the official record.

↑